Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
12.17
-0.08 (-0.65%)
At close: Feb 21, 2025, 4:00 PM
12.14
-0.03 (-0.25%)
After-hours: Feb 21, 2025, 6:44 PM EST
Intellia Therapeutics Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for Intellia Therapeutics stock have an average target of 50.53, with a low estimate of 11 and a high estimate of 120. The average target predicts an increase of 315.20% from the current stock price of 12.17.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Intellia Therapeutics stock from 18 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 | 5 | 5 |
| Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Hold | 4 | 5 | 5 | 5 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 17 | 17 | 17 | 18 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $56 → $11 | Buy → Hold | Downgrades | $56 → $11 | -9.61% | Jan 27, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $20 → $12 | Hold | Maintains | $20 → $12 | -1.40% | Jan 14, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $60 → $40 | Buy | Maintains | $60 → $40 | +228.68% | Jan 13, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $70 → $60 | Buy | Maintains | $70 → $60 | +393.02% | Jan 10, 2025 |
| BMO Capital | BMO Capital | Buy Maintains $70 → $50 | Buy | Maintains | $70 → $50 | +310.85% | Jan 10, 2025 |
Financial Forecast
Revenue This Year
54.66M
from 36.28M
Increased by 50.68%
Revenue Next Year
54.16M
from 54.66M
Decreased by -0.92%
EPS This Year
-5.42
from -5.42
EPS Next Year
-5.22
from -5.42
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 65.6M | 220.5M | 105.0M | |||
| Avg | 54.7M | 54.2M | 42.8M | |||
| Low | 44.1M | n/a | 6.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 80.9% | 303.4% | 93.9% | |||
| Avg | 50.7% | -0.9% | -21.0% | |||
| Low | 21.6% | - | -87.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -5.08 | -3.24 | -3.37 | |||
| Avg | -5.42 | -5.22 | -5.31 | |||
| Low | -5.49 | -6.64 | -7.03 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.